Tamsulosin reduces nighttime urine production in benign prostatic hyperplasia patients with nocturnal polyuria: A prospective open-label long-term study using frequency-volume chart

Neurourology and Urodynamics

Volumn 31, Issue 1, 2012, Pages 80-85

  Kojima, Yoshiyuki ^a   Sasaki, Shoichi ^a   Imura, Makoto ^a   Kubota, Yasue ^a   Hayashi, Yutaro ^a   Kohri, Kenjiro ^a  

^a NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

Author keywords

1 AR antagonist; benign prostatic hyperplasia; long term; nocturia; nocturnal polyuria

Indexed keywords

TAMSULOSIN;

ADULT; AGED; CLINICAL ASSESSMENT TOOL; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; FREQUENCY VOLUME CHART; HUMAN; INTERNATIONAL PROSTATE SYMPTOM SCORE; LOWER URINARY TRACT SYMPTOM; MAJOR CLINICAL STUDY; MALE; NOCTURNAL ENURESIS; OPEN STUDY; PROSPECTIVE STUDY; PROSTATE HYPERTROPHY; QUALITY OF LIFE INDEX; REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; URINARY FREQUENCY; URINE FLOW RATE; URINE LEVEL; URINE VOLUME; UROFLOWMETRY;

ADRENERGIC ALPHA-1 RECEPTOR ANTAGONISTS; AGED; CIRCADIAN RHYTHM; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; NOCTURIA; POLYURIA; PREVALENCE; PROSPECTIVE STUDIES; PROSTATIC HYPERPLASIA; QUALITY OF LIFE; SULFONAMIDES; TREATMENT OUTCOME; URINE; URODYNAMICS;

EID: 84856225499     PISSN: 07332467     EISSN: 15206777     Source Type: Journal    
DOI: 10.1002/nau.21224     Document Type: Review

References (26)

1. Narayan P, Tewari A,. A second phase III multicenter placebo controlled study of 2 dosages of modified release tamsulosin in patients with symptoms of benign prostatic hyperplasia. United States 93-01 Study Group. J Urol 1998; 160: 1701-06.
2. Lepor H,. Long-term evaluation of tamsulosin in benign prostatic hyperplasia: Placebo-controlled, double-blind extension of phase III trial. Tamsulosin Investigator Group. Urology 1998; 51: 901-6.
3. Chapple CR, Wyndaele JJ, Nordling J, et al. Tamsulosin, the first prostate-selective alpha 1A-adrenoceptor antagonist. A meta-analysis of two randomized, placebo-controlled, multicentre studies in patients with benign prostatic obstruction (symptomatic BPH). European Tamsulosin Study Group. Eur Urol 1996; 29: 155-67.
4. Roehborn CG,. Efficacy of alpha-adrenergic receptor blockers in the treatment of male lower urinary tract symptoms. Rev Urol 2009; 11: S1-8.
5. Appell RA, Sand PK,. Nocturia: Etiology, diagnosis, and treatment. Neurourol Urodyn 2008; 27: 34-9.
6. Van Kerrebroeck PE, Dmochowski R, FitzGerald MP, et al. Nocturia research: Current status and future perspectives. Neurourol Urodyn 2010; 29: 623-8.
7. Milsom I, Abrams P, Cardozo L, et al. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int 2001; 87: 760-6.
8. Van Kerrebroeck P, Abrams P, Chaikin D, et al. The standardization of terminology in nocturia: Report from the Standardisation Subcommittee of the International Continence Society. Neurourol Urodyn 2002; 21: 179-83.
9. Kujubu DA, Aboseif SR,. An overview of nocturia and the syndrome of nocturnal polyuria in the elderly. Nat Clin Pract Nephrol 2008; 4: 426-35.
10. Chapple CR, Carter P, Christmas TJ, et al. A three month double-blind study of doxazosin as treatment for benign prostatic bladder outlet obstruction. Br J Urol 1994; 74: 50-6.
11. Abrams P, Schulman CC, Vaage S,. Tamsulosin, a selective alpha 1c-adrenoceptor antagonist: A randomized, controlled trial in patients with benign prostatic 'obstruction' (symptomatic BPH). The European Tamsulosin Study Group. Br J Urol 1995; 76: 325-36.
12. Roehrborn CG, Van Kerrebroeck P, Nordling J,. Safety and efficacy of alfuzosin 10 mg once-daily in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: A pooled analysis of three double-blind, placebo-controlled studies. BJU Int 2003; 92: 257-61.
13. Linsell CR, Lightman SL, Mullen PE, et al. Circadian rhythms of epinephrine and norepinephrine in man. J Clin Endocrinol Metab 1985; 60: 1210-5.
14. Shea SA, Hilton MF, Muller JE,. Clinical hypertension and vascular diseases. In:, White WB, editor. Blood pressure monitoring in cardiovascular medicine and therapeutics. Totowa, NJ: Humana Press Inc; 2007. pp 253-91.
15. Wang CJ, Lin YN, Huang SW, et al. Low dose oral desmopressin for nocturnal polyuria in patients with benign prostatic hyperplasia: A double-blind, placebo controlled, randomized study. J Urol 2011; 185: 219-23.
16. Yoshimura K, Ohara H, Ichioka K, et al. Nocturia and benign prostatic hyperplasia. Urology 2003; 61: 786-90.
17. Homma Y, Yamaguchi T, Kondo Y, et al. Significance of nocturia in the International Prostate Symptom Score for benign prostatic hyperplasia. J Urol 2002; 167: 172-6.
18. Mariappan P, Turner KJ, Sothilingam S, et al. Nocturia, nocturia indices and variables from frequency-volume charts are significantly different in Asian and Caucasian men with lower urinary tract symptoms: A prospective comparison study. BJU Int 2007; 100: 332-6.
19. Takahashi S, Tajima A, Matsushima H, et al. Clinical efficacy of an alpha1A/D-adrenoceptor blocker (naftopidil) on overactive bladder symptoms in patients with benign prostatic hyperplasia. Int J Urol 2006; 13: 15-20.
20. Yoshida M, Inadome A, Masunaga K, et al. Effectiveness of tamsulosin hydrochloride and its mechanism in improving nocturia associated with lower urinary tract symptoms/benign prostatic hyperplasia. Neurourol Urodyn 2010; 29: 1276-81.
21. McKeigue PM, Reynard JM,. Relation of nocturnal polyuria of the elderly to essential hypertension. Lancet 2005; 355: 486-8.
22. Matthiesen TB, Rittig S, NÃrgaard JP, et al. Nocturnal polyuria and natriuresis in male patients with nocturia and lower urinary tract symptoms. J Urol 1996; 156: 1292-9.
23. Sugaya K, Nishijima S, Oda M, et al. Biochemical and body composition analysis of nocturia in the elderly. Neurourol Urodyn 2008; 27: 205-11.
24. Villalobos-Molina R, Lõpez-Guerrero JJ, Ibarra M,. Alpha 1D- and alpha 1A-adrenoceptors mediate contraction in rat renal artery. Eur J Pharmacol 1997; 322: 225-7.
25. Armenia A, Sattar MA, Abdullah NA, et al. Alpha1A- and alpha1D-adrenoceptors are the major functional subtypes of renal alpha1-adrenoceptors in streptozotocin-induced diabetic and normal Sprague-Dawley rats. Auton Autacoid Pharmacol 2008; 28: 1-10.
26. Fujii T, Sugiura T, Ohkita M, et al. Selective antagonism of the postsynaptic alpha(1)-adrenoceptor is protective against ischemic acute renal failure in rats. Eur J Pharmacol 2007; 28: 185-91.